Procedures-Calves were randomly allocated to 1 of 2 treatment groups. Control calves (n = 10/replicate) received a combination modified-live mixed viral vaccine without BHV-1,
and treatment calves (20 and 23/replicate) received a combination modified-live mixed viral vaccine containing BHV-1. Each group was challenged via aerosol with 1 of 2 field strains of BHV-1, 30 days after vaccination in replicate 1 and 97 days after vaccination in replicate 2. After challenge, calves were commingled in 1 drylot pen. Clinical signs, immune responses, and nasal shedding of virus were monitored for 10 days after challenge, SNX-5422 mouse after which the calves were euthanatized and tracheal lesions were assessed.
Results-Vaccination stimulated production of BHV-1-specific IgG antibody that cross-neutralized several field and laboratory strains of BHV-1. Challenge with both field strains of BHV-1 resulted in moderate to severe respiratory tract disease in control calves. Treatment calves had significantly fewer signs of clinical disease, shed less BHV-1, had less or EVP4593 solubility dmso no weight loss after challenge, and had fewer tracheal lesions than control calves for at least 97 days after vaccination.
Conclusions and Clinical Relevance-Administration of the combination modified-live BHV-1 vaccine yielded significant disease-sparing
effects in calves experimentally infected with virulent field strains of BHV-1. selleck screening library (J Am Vet Med Assoc 2009;235:563-572)”
“Ginsenoside Re (G-Re) is a major ingredient of the ginseng bud. A novel and rapid method to isolate and purify G-Re from ginseng buds was established. The procedure involves solvent extraction of ginseng bud powder, then pre-purification with an active carbon column and purification by preparative HPLC (prep-HPLC). Active carbon, which can selectively adsorb other kinds of ginsenosides except G-Re, was used as a new media to pre-purify G-Re in this study. In addition, we describe the development and optimisation of prep-HPLC parameters for G-Re purification. Compared to other types of high-purity G-Re preparation methods, this method is efficient, economical, waste-conscious
and has the potential to maximise.”
“In lung transplant recipients (LTRs), severe clinical complications, such as microbial infections of the lung or transplant rejection, may occur. Surfactant protein D (SP-D) is a C-type lectin that is mainly produced in alveolar type II cells. Plasma SP-D levels are usually low, but may increase when the lung-blood barrier is impaired. In this study, we analyzed whether plasma SP-D concentrations reflect rejection or infection of the lung allograft. An enzyme-linked immunosorbent assay was used to measure SP-D levels in plasma samples from 58 LTRs during intervals without pathologic respiratory findings and during episodes of acute cellular rejection (ACR), microbial colonization, and microbial pneumonia.